Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome

European Heart Journal

Volumn 25, Issue 4, 2004, Pages 349-355

  Trøseid, Marius ^a   Lappegård, Knut T ^a,b   Claudi, Tor ^c   Damås, Jan K ^d   Mørkrid, Lars ^d   Brendberg, Randi ^a   Mollnes, Tom E ^d  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c Rønvik Health Center   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Atherosclerosis; Chemokines; Exercise; Inflammation; Metabolic syndrome; Visceral fat

Indexed keywords

CHEMOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 8; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN;

ADULT; ANTHROPOMETRY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EXERCISE; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VISCERA;

ADULT; BLOOD GLUCOSE; CHEMOKINE CCL2; EXERCISE THERAPY; HUMANS; INFLAMMATION; INTERLEUKIN-8; LIPIDS; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 10744233017     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.12.006     Document Type: Article

References (42)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
2. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002;324:939-42.
3. Claudi T, Midthjell K, Holmen J et al. Cardiovascular disease and risk factors in persons with type 2 diabetes diagnosed in a large population screening: the Nord-Trondelag Diabetes Study, Norway. J Intern Med 2000;248:492-500.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
5. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002;160:91-102.
6. Koenig W, Sund M, Frohlich M et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
7. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-8.
8. Ridker PM, Buring JE, Cook NR et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-7.
9. Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
10. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol 1999;36:949-55.
11. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. Eur Heart J 2002;23:831-4.
12. Gerhardt CC, Romero IA, Cancello R et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 2001;175:81-92.
13. Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
14. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999;10:19-29.
15. Despres JP, Bouchard C, Tremblay A et al. Effects of aerobic training on fat distribution in male subjects. Med Sci Sports Exerc 1985;17:113-8.
16. Treuth MS, Ryan AS, Pratley RE et al. Effects of strength training on total and regional body composition in older men. J Appl Physiol 1994;77:614-20.
17. Torjesen PA, Birkeland KI, Anderssen SA et al. Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. Diabetes Care 1997;20:26-31.
18. Bickel C, Rupprecht HJ, Blankenberg S et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002;82:25-31.
19. Lemieux I, Pascot A, Couillard C et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84.
20. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
21. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators [see comments]. N Engl J Med 1996;335:1001-9.
22. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels [see comments]. N Engl J Med 1998;339:1349-57.
23. Kvist H, Chowdhury B, Sjostrom L et al. Adipose tissue volume determination in males by computed tomography and 40K. Int J Obes 1988;12:249-66.
24. Mollnes TE. Analysis of in vivo complement activation. In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, editors. Weir's Handbook of Experimental Immunology. Boston, MA: Blackwell Science; 1997, p. 78.1-8.
25. Pedersen BK, Steensberg A, Fischer C et al. Exercise and cytokines with particular focus on muscle-derived IL-6. Exerc Immunol Rev 2001;7:18-31.
26. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002;13:561-8.
27. Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med 2002;162:1286-92.
28. Damås JK, Gullestad L, Ueland T et al. CXC-chemokines, a new group of cytokines in congestive heart failure - possible role of platelets and monocytes [see comments]. Cardiovasc Res 2000;45:428-36.
29. Adamopoulos S, Parissis J, Kroupis C et al. Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J 2001;22:791-7.
30. Waehre T, Damås JK, Gullestad L et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003;41:1460-7.
31. Romano M, Diomede L, Sironi M et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000;80:1095-100.
32. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998;9:397-405.
33. Gerszten RE, Garcia-Zepeda EA, Lim YC et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999;398:718-23.
34. Ikeda U, Matsui K, Murakami Y et al. Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol 2002;25:143-7.
35. de Lemos JA, Morrow DA, Sabatine MS et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107:690-5.
36. Leon AS, Connett J, Jacobs DR Jr et al. Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. JAMA 1987;258:2388-95.
37. Temaru R, Urakaze M, Satou A et al. High glucose enhances the gene expression of interleukin-8 in human endothelial cells, but not in smooth muscle cells: possible role of interleukin-8 in diabetic macroangiopathy. Diabetologia 1997;40:610-3.
38. Yudkin JS, Stehouwer CD, Emeis JJ et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999;19:972-8.
39. Okada M, Matsumori A, Ono K et al. Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:894-901.
40. Maiorana A, O'Driscoll G, Cheetham C et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 2001;38:860-6.
41. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
42. Myers J, Prakash M, Froelicher V et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002;346:793-801.